Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q4U2R6
UPID:
RM51_HUMAN
Alternative names:
39S ribosomal protein L51, mitochondrial; bMRP-64
Alternative UPACC:
Q4U2R6; Q96Q57; Q9BQ36; Q9P0N7
Background:
The Large ribosomal subunit protein mL51, also known as 39S ribosomal protein L51, mitochondrial and bMRP-64, plays a crucial role in the mitochondrial ribosome. Its primary function is to facilitate protein synthesis within the mitochondria, a process essential for cellular energy production and metabolic functions.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL51 could open doors to potential therapeutic strategies. Its pivotal role in mitochondrial protein synthesis makes it a key target for research aimed at addressing mitochondrial disorders and enhancing cellular energy production.